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Synopsis
The importance of growth and maintenance of skeletal muscle is vital for long term health and quality of life.
Appropriate nutrition with specific bioactivities relevant to the functionalities of tissues such as skeletal muscle,
can assist in maintaining and promoting adaptive responses to biological and environmental stresses which prevent
muscle atrophy and promote hypertrophy. The aim of this investigation was to develop a novel in vitro cell-based
electric impedance assay to study myoblast to myotube formation on the real time cell analysis (RTCA) platform
(xCELLigenceTM, ACEA) and to validate the system by testing myotube responses to hypertrophic stimuli. C2C12
myoblasts were proliferated until 70% confluent in Dulbecco’s Modified Eagles Medium (DMEM) (10% FBS) and
subsequently differentiated to myotubes over 8 days in DMEM [2% horse serum (HS)]. Changes in cell behaviour
and adhesion properties were monitored by measuring impedance via interdigitated microelectrodes in the base of
E-16 cell culture dishes. To establish the suitability of this assay to monitor nutrient regulation of muscle hypertrophy,
leucine, a known potent regulator of MPS was then supplemented to the fully formed myotubes in physiologically
relevant conditions – 0.20 mM, 0.40 mM, 0.6 mM, 0.8 mM and above 1.0 mM, 1.5 mM, 2.0 mM and impedance
subsequently monitored. Parallel experiments highlighting alterations in myotube thickness, muscle protein synthesis
(MPS) (mammalian target of rapamycin; mTOR) and differentiation (myogenin) were conducted to support RTCA
bioassay findings. This in vitro bioassay can be used to monitor skeletal muscle behaviour and identify nutrient
compounds with bioactivities promoting skeletal muscle hypertrophy, reducing muscle atrophy and thus inform the
development of novel nutrient formulations for the maintenance of skeletal muscle.
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INTRODUCTION
Skeletal muscle is the largest organ in the human body compris-
ing of approximately 50 % of our total body mass [1]. The func-
tion of the skeletal muscle is to maintain the skeleton, moving,
breathing and thermoregulation and is also an important determ-
inant in over-all body health [2]. Maintaining healthy muscle
mass is a critical factor in metabolic health, bone strength, body
weight control and resilience to stress and disease. Muscle mass
is regulated by a balance of muscle protein synthesis (MPS)
and muscle protein breakdown (MPB), the rate of which can be
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altered through nutrition, age, exercise and sexual dimorphism
[3]. Defects in skeletal muscle growth and metabolism can lead to
diseases such as diabetes, obesity, heart disease and rheumatoid
arthritis [4–6]. Healthy muscle mass promotes overall general
good health, therefore preventing many pathologic conditions
and chronic diseases [2].
C2C12 cells are a primary murine myoblast cell line, a
subclone of C2 myoblasts. These cells are mononucleated,
fusiform structures which progressively fuse to form plurinuc-
leate syncytia that further differentiate in culture to acquire the
morpho-functional features of the muscle cells [7–9]. Differenti-
ation of skeletal muscle from myoblasts to myotubes in vitro is an
c© 2016 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
Licence 4.0 (CC BY).
1
S.M. Murphy and others
important tool to facilitate investigations of the mechanisms
which regulate muscle mass development and maintenance.
The C2C12 cell line is a well-established mouse myoblast
cell line used widely as an in vitro model of skeletal muscle
[9–11]. Manipulation of cell culture conditions triggers fusion
of the mononucleated C2C12 myoblasts to form multi-nucleated
myotube muscle fibres. The relative thickness of these myotubes
in response to treatment with either atrophic or hypertrophic
agents can be used as an indicator of MPB or MPS [12,13].
However, the end point nature of many traditional cell-based
assays, as well as the challenges associated with measuring
myotube thickness e.g. difficulty in measurement of very small
atrophic or hypertrophic changes, have hindered our ability to
fully utilize this cell line as a screening tool for compounds that
can have an effect on muscle mass.
The real time cell analysis (RTCA) xCELLigenceTM system
has previously been investigated as a potential tool to monitor
cell behaviour in real time [13–18]. The xCELLigenceTM sys-
tem allows highly sensitive, label free, non-invasive monitoring
of cell proliferation and cell behaviour in real time using micro
electric cell sensor arrays integrated into the bottom of tissue cul-
ture plates [14,19]. Electrical impedance through the sensor elec-
trodes is monitored and changes in impedance indicate changes
in adherence and growth of cells. Change in impedance is recor-
ded as a cell index (CI) value which is a relative, dimensionless
value representative of the change in impedance divided by the
background value. RTCA is highly accurate when compared with
end point assays and has the added advantage of regular monitor-
ing of cellular response to compounds over the entire experiment
without any interruption [20].
The aim of the present study was to optimize and valid-
ate the use of the xCELLigenceTM system to monitor myotube
formation from undifferentiated myoblast C2C12 cells. Here,
we have developed a complete protocol for optimal differenti-
ation of C2C12 cells from myoblasts to myotube muscle fibres
using the xCELLigenceTM system and validated this against tra-
ditional proteomic and microscopy methods. We describe the
optimum conditions to ensure maximum formation of healthy
myotubes. We have used proteomics throughout to track markers
of the full differentiation process. In order to validate the applic-
ation and sensitivity of this system further, we also describe the
dose-dependent effect of a known hypertrophic agent, leucine,
on myotubes as monitored on the xCELLigenceTM system. We
are confident that this method will facilitate future investigation
of the atrophic or hypertrophic effects of compounds on skeletal
muscle and will be used as a useful tool to inform and expand our
current knowledge of the mechanisms regulating MPS and MPB.
MATERIALS AND METHODS
Cell culture
C2C12 cells, a sub clone of C2 myoblasts, were obtained from
ATCC® CRL1772, Manassas, VA (Lot number 60339292). Cells
were cultured in a 10 % complete media (CM), Dulbecco’s Mod-
ified Eagles Medium (DMEM) (D6429, Sigma–Aldrich) sup-
plemented with 10 % (v/v) FBS (F7524, Sigma–Aldrich), 1 %
(v/v) penicillin/streptomycin (P0781, Sigma–Aldrich) and 1 %
L-glutamine (G7513, Sigma–Aldrich). Undifferentiated myo-
blasts were maintained at 37 ◦C in a 5 % CO2 humidified atmo-
sphere. To induce myoblast fusion, cells were allowed to reach
70 % confluence before being switched to a differentiation me-
dia (DM), – DMEM (D6429, Sigma–Aldrich) supplemented with
2 % (v/v) horse serum (HS). Myotube progression was monitored
over the next 8 days until full myotube formation was achieved.
Media was changed every 24 h, until the day of testing whereby
compounds of interest were added.
Preparation of cellular protein lysates
Cellular protein extracts were prepared by placing cells on ice,
removing media and washing three times in ice cold phosphate
buffered saline. Cells were scraped into ice cold lysis buffer
(10 mM Tris/HCl pH 7.4, 150 mM NaCl, NaF, 1 % NP40) plus
the tyrosine phosphatase inhibitor Na3VO4 (1 mM), protease in-
hibitors phenylmethanesulfonyl fluoride (PMSF) (1 mM), pep-
statin (1 μM) and aprotinin (1.5 μg/ml). Lysates were incubated
on ice for 20 min before centrifugation at 130 g for 15 min at
4 ◦C to remove nuclei and cellular debris. Lysates were analysed
for protein concentration using the Bradford assay and boiled in
sample buffer for SDS/PAGE (sodium dodecyl polyacrylamide
gel electrophoresis).
Western Blot analysis
Equal amounts of total protein were run on a 12 % running and
a 4 % stacking SDS polyacrylamide gel. Proteins captured in the
gel were transferred to a nitrocellulose membrane. The membrane
was blocked for 1 h in 5 % skimmed milk (w/v) in TBS-T con-
taining 0.5 % Tween-20. Membranes were incubated overnight at
4 ◦C in a primary antibody. Primary antibody dilutions were anti-
myogenin 1:1000 TBS-T/5 % skimmed milk (Santa Cruz (F5D:
sc12732)), anti-mTOR 1:1000 TBS-T/5 % skimmed milk (Cell
Signalling (7C10)). Membranes were then washed for 5 min in
0.05 % T-BST, repeated three times, and incubated with an appro-
priate secondary antibody (IRDye® 680LT and 800CW-Infrared
Dye coupled anti-rabbit or anti-mouse, I-COR Biosciences).
Antibody reactive bands were detected with the Odyssey® in-
frared imaging system (LI-COR Biosciences). Band intensities
were quantified using Odyssey CLx Western Blot Developer
System.
Cell index measurement
Label free, non-invasive, electric impedance measurements were
taken using the xCELLigenceTM RTCA Instrument from ACEA.
Using a proprietary microelectronic E-16 View gold plated
base sensor plate developed by ACEA Biosciences, an auto-
mated reading of cell status is taken in real time throughout the
myoblast to myotube formation cycle. C2C12 myoblasts were
seeded at a density of 0.5 × 104 . CI recordings were taken
every 15 min during the myoblast proliferation and myotube
formation.
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Hypertrophic analysis
Myotubes were formed as described above. On the day of exper-
imentation, myotubes were amino acid and serum starved for 4 h
prior to the addition of a range of concentrations of leucine diluted
in amino acid free media. Amino acid free DMEM media (D9807-
10) was purchased from Life Technologies supplemented with
1 % (v/v) penicillin/streptomycin (P0781, Sigma–Aldrich), 1 %
sodium pyruvate (Thermo Fisher), 1 % L-glutamine (G7513,
Sigma–Aldrich) and 6 mM D-glucose (G7201 Sigma). Leucine
(L8912 Sigma) was purchased from Sigma–Aldrich. CI was re-
corded every 15 min throughout the duration of the experiment.
Phase microscopy – hypertrophy/atrophy analysis
Images of myogenic differentiation were taken using Olympus
cellSens Dimension 1.12. Copyright c© 2009–2014 OLYMPUS
CORPORATION Core Version XV 3.11 (Build 12849) Pack-
age number 5900 (cellSens Dimension). Labelling and detec-
tion probes Nucblue live stain (R37605) and Actin green 488
(R37110) was purchased from Life Technologies. Images were
saved as JPEG images and analysed using ImageJ to measure
changes in myotube thickness.
RESULTS
Determination of the optimal cell number and
differentiation time of C2C12 cells on the RTCA
xCELLigenceTM System
To determine the optimum cell number to achieve the best time
to begin myotube differentiation on this platform (70 % con-
fluency in high serum media (7)), a titration experiment was
carried out (Figure 1A) to monitor myoblast behaviour. My-
oblasts were seeded at densities of 1000 cells per well up to
20000 cells per well (all data not shown). Significantly differ-
ent behaviour was observed when a variety of seeding dens-
ities were used on the xCELLigenceTM platform (Figure 1A).
Myoblasts were cultured using E-16 VIEW plates in a 10 %
FBS media, and monitored until they reached 70 % conflu-
ence. These plates have rows of microelectrode sensors removed
within the centre of the base of the plate to facilitate clearer
imaging of cell performance while still enabling impedance
measurement from the xCELLigenceTM platform. 70 % conflu-
ency was achieved after 30 h when cells were seeded at 5000
cells per well (Figure 1B (iii)). Using traditional growth as-
says, we illustrate that cells are proliferating during this time
(Figure 1C).
After 30 h of proliferation, the 10 % FBS media was replaced
with a differentiation media containing 2 % HS media (see Ma-
terials and Methods). This facilitates the fusion of mononuc-
leated myoblasts to form multi-nucleated, elongated, post mitotic
myotubes. An overview of the cell performance to complete pro-
gression of differentiated myotubes on the RTCA platform after
changing to differentiation media (Days 0–8) is shown in Fig-
ure 2(A). This progression was monitored over the duration of
the assay in parallel using traditional phase contrast imaging at
key time points (Figure 2B). The xCELLigenceTM graph indic-
ated that 5000 cells per well out-performed all other cell densities,
showing a higher CI and provided a more suitable ratio for myo-
blast fusion and optimal conditions for myotube formation. Phase
contrast images of the different cells demonstrate progression of
myoblasts to myotubes using different seeding densities (1000,
3000, 5000 and 7000) taken on Days 1 ( + 54 h), 3 ( + 108 h), 5
( + 150 h) and 7 ( + 208 h) of the assay. This supports the RTCA
data and illustrates that a seeding density of 5000 cells/well is
optimal for myotube formation over 8 days. Plating at higher
cell densities (7000) resulted in cells reaching myoblast cell
saturation and confluency at 30 h. These myoblasts were over-
crowded and the cells appeared unhealthy resulting in a signi-
ficant increase in cell death and sub-optimal myotube formation
(Figure 2B (xiii–xvi)). Cells seeded at a density below 5000 took
a longer period of time to proliferate to 70 % and myotube forma-
tion is significantly hindered (Figure 2A (red line)). Both high and
low densities will ultimately limit the performance and timing of
subsequent assays. Our results show that seeding C2C12 skeletal
muscle cells at 5000 cells per 0.32 cm2 well area enabled pro-
liferation to 70 % confluency earlier than either 1000/3000 cells
when differentiated at this number and time point, displayed
higher viability and improved myotube formation than higher
seeding densities (7000).This seeding density was adopted as
optimal for all further experimentation. This is in agreement with
the findings of previous muscle cell culture research [7,13].
Validation of the xCELLigenceTM system as a tool
to measure skeletal muscle cell behaviour
Having optimized the performance of C2C12 skeletal muscle
cells on the xCELLigenceTM platform, the next step was to
validate the system’s measurement of cell behaviour. To monitor
the robustness of the myotube formation at 5000 cells/well, we
seeded several different wells and examined the growth profile
by RTCA. As expected, all wells returned identical graphs
with low standard deviations and high levels of reproducibility
(Figure 3A). After seeding the cells, we observe an increase
in CI in the initial 2–3 h which represents cell adhesion to
the plates (Figure 3A). From this point to 30 h we observe
an increase in CI due to increased cell number as a result
of proliferation (Figure 1C). From 30 to 78 h (Days 1–3),
we see no further proliferation or increase in cell number
(Figures 2B and 3B), however, we observe an increase in CI due
to the initial fusion of cells that occurs during differentiation
(Figure 3A). From Days 4 to 8 (to 220 h) we see no further
increase in CI (Figure 3A). We use microscopy to illustrate that
through the differentiation process, there is myoblast fusion
and differentiation to myotubes (Figures 3B). In parallel, we
looked at well-known markers of myotube differentiation to
validate our RTCA approach (Figure 3C). The mammalian target
of rapamycin (mTOR) is a key regulator of protein synthesis
and muscle formation and myogenin is an established marker
of skeletal muscle differentiation [21–24]. We examined the
expression levels of mTOR and myogenin on each day of
proliferation and differentiation (Figure 3C) and found an
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Figure 1 Titration experiment to determine the optimal cell culture number and differentiation time of C2C12 cells
C2C12 cells were seeded at a range of titrations – 1000, 3000, 5000 and 7000 in duplicate on E-16 VIEW plates that
were monitored every 10 min for 30 h. (A) Representative graph comparing the growth curve (0–30 h) for 1000 (red), 3000
(green), 5000 (blue) and 7000 (purple) cells. (B) Images representing E-16 VIEW plates that were observed using phase
contrast for – (i) 1000, (ii) 3000, (iii) 5000 and (iv) 7000 cells at 30 h. (C) Cells were trypsinized at 30 h and counted for
each seeding density demonstrating cell proliferation from 0 to 30 h. Data are presented as mean +− S.D.
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Figure 2 Formation of myotubes over 220 h at different seeding densities
C2C12 cells were seeded at a range of densities – 1000 (red), 3000 (green), 5000 (blue), 7000 (pink) cells in duplicate
in E-16 VIEW plates and monitored every 10 min over 220 h. (A) CI of myoblast to myotube formation over 220 h. (B)
Images representing cells seeded at 1000, 3000, 5000, 7000 all of which were differentiated at 30 h and imaged on Day
1 ( + 54 h), Day 3 ( + 108 h), Day 5 ( + 150 h), Day 7 ( + 208 h). Scale bars are 100 μM.
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Figure 3 Formation of myotubes and markers of differentiation over 220 h at optimal seeding density
(A) Represents CI of myotube formation using 5000 cells per well on the xCELLigenceTM over 220 h. (B) Fluorescent
images with actin (green) and nuclear (blue) staining representing cells seeded at 5000 cells per well and imaged on
Day 2 ( + 78 h), Day 4 ( + 126 h), Day 6 ( + 174 h) and Day 8 ( + 220 h). (C) Proteomic analysis of markers of myotube
differentiation (myogenin, mTOR) over 220 h extracted from lysates taken every 24 h throughout myotube formation.
increase in the expression of both pathways that correlated
directly with the timing of our myotube formation. Taken to-
gether, these data indicate that we can seed C2C12 cells at 5000
cells/well and differentiate over 8 days using the RTCA platform
to monitor their differentiation into myotubes that can be
validated using known biochemical checkpoints and microscopy.
Validation of the use of the xCELLigenceTM
platform to monitor myotube size as illustrated
using a known hypertrophic agent
To establish the suitability of this assay to monitor nutrient reg-
ulation of muscle hypertrophy in physiologically relevant condi-
tions, C2C12 skeletal muscle myotubes were serum and amino
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acid starved for 4 h. Physiologically relevant concentrations of
leucine (200 μM, 400 μM, 600 μM, 800 μM), a known potent
regulator of MPS, were then added to amino acid free media
as described in Materials and Methods. CI was recorded for
the next 12 h (2 h shown in Figure 4A). The data were normal-
ized to a point 4 h post amino acid depravation and just prior
to the addition of the hypertrophic agent. The dose-dependent
hypertrophic changes were measured post addition of leucine.
A dose–response effect was observed with a 32 % increase in
CI after 2 h in the presence of 2.0 mM leucine (Figure 4B).
To validate our approach, images of myotubes post addition of
leucine were taken at 4× magnification and myotube thickness
was measured using ImageJ [25] and compared with images
taken prior to the addition of leucine. We observed a 27 % in-
crease in cell thickness after 2 h in the presence of 2.0 mM leu-
cine when compared with control myotubes (Figure 4C). This
clearly demonstrates the ability of the xCELLigenceTM system
to measure myotube size changes in response to hypertrophic
stimuli.
DISCUSSION
The purpose of the present study was to develop a bioassay to
monitor growth and formation of muscle myotubes in real time
using the xCELLigenceTM Real Time Cell Analyser (RTCA) in-
strument. The primary outcome of the present study is a detailed
methodology of the seeding, proliferation and differentiation of
C2C12 skeletal muscle cells to fully formed myotubes. We have
also validated the xCELLigenceTM system for the monitoring of
proliferation of myoblasts, and for monitoring changes in fully
differentiated myotubes in response to a hypertrophic agent (leu-
cine). This confirms the use of RTCA platforms for medium
throughput monitoring of muscle cell behaviour.
C2C12 cells have been used in previous studies to investigate
muscle behaviour [10,26], but are difficult to monitor because of
extreme heterogeneity [13]. This label free, non-invasive platform
allows us to measure cell proliferation and myotube perform-
ance in uninterrupted monitoring expressed as a CI value. The
essence of the system is the microelectronic cell sensor arrays
that are integrated into the bottom of the plate wells. Measur-
ing the electrical impedance on the sensor electrodes indicates
the changes in the cells on the electrodes and is recorded. The
CI is a relative and dimensionless value since it represents the
impedance change divided by the background value. Unlike ‘end-
point’ assays, the xCELLigenceTM allows the monitoring of the
entire experiment in real time without interruption. The RTCA
instrument has been developed to study cell activity based on
electronic detection of biological assay processes, amalgamating
molecular and cell biology with microelectronics. Evaluating the
electronic properties of sensor surfaces provide important data
about the biological status of the cells or proteins present on
the sensors. As changes occur in the biological status of cells
or proteins the xCELLigenceTM Instrument automatically meas-
ures the corresponding development in the electronic properties
of the sensors near the cells. These analogue electronic readout
signals are then converted to digital signals for processing and
analysis [27].
We first established a cell number suitable for the instrument
using a titration assay. Five thousand cells were demonstrated as
the best performing condition within the E-16 Plate as this seeding
density enables timely adhesion of the cells to the plate, progres-
sion to 70 % confluency within 30 h and increased myotube form-
ation and cell viability. Once myoblasts reached 70 % confluence
(30 h), growth factors in the media were reduced and differenti-
ation of C2C12 cell myoblasts began. Myoblasts withdraw from
the cell cycle and fuse to form post mitotic multinucleated, elong-
ated myotubes. We monitored the myotube progression in parallel
using the xCELLigenceTM system supported by microscopy, and
proteomics using a well-known marker of MPS, mTOR a crit-
ical signalling pathway involved in regulating protein synthesis
[28–33], and myogenin, a muscle specific transcription factor
involved in myogenesis [24]. Western Blot analysis showed an
increase in expression of mTOR and myogenin as myotubes were
cultured indicating progressive myotube formation and increase
in size (Figure 3C). The entire process is illustrated by schematic
overview (Figure 5).
Leucine, a known potent regulator of MPS [34–37] was used
to validate the sensitivity of the bioassay to myotube size. Dif-
ferent physiologically relevant concentrations of leucine were
applied on to the fully formed myotubes after 8 days. Myotubes
were monitored every 15 min post application. An increase in CI
observed indicated a dose-dependent rise in myotube thickness
in response to Leucine. A comparable increase in myotube dia-
meter was confirmed by microscopy in response to leucine using
ImageJ software [38].
Great advances have been made in understanding the regula-
tion of skeletal muscle mass both molecularly and physiologically
but the scientific community lack robust reproducible assays to
monitor muscle formation and performance in the presence of test
compounds using miniaturized and medium to high throughput
assays. In the present study we illustrate that we can accurately
and sensitively trace small changes in myoblast cell morpho-
logy behaviour in real time through myogenic differentiation and
myotube formation in response to a hypertrophic agent. The prac-
tical implications of the present study are critical, suggesting that
hypertrophic dietary supplements and recovery compounds for
both the aging population and post exercise patrons could poten-
tially be tested on this reproducible, high throughput bioassay.
Here we have described an experimental design and workflow
(Figure 5) that allows us to monitor the differentiation and per-
formance of muscle myotubes in real time over 8 days and a post
differentiation period in which myotube size/behaviour can be
monitored. This method represents a more accurate and in depth
account of the C2C12 differentiation process on this real time
platform. The application of real-time myogenic analysis could
further help investigate changes in muscular mass when subject
to hypertrophic/atrophic compounds which would prove salubri-
ous when applied to growth and recovery supplement to promote
healthy muscle mass.
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Figure 4 Validation of the sensitivity of myotube performance on the xCELLigenceTM system using a known hypertrophic
stimuli
(A) CI was normalized on Day 8 prior to the addition of 200 μM (light green), 400 μM (dark blue), 600 μM (pink), 800 μM
(light blue), 1.0 mM (purple), 1.5 mM (brown) and 2.0 mM (dark green) leucine. Dose dependent changes in CI were
measured every 15 min post addition of leucine (n=4). (B) Quantification of CI changes relative to hypertrophic response
to different concentrations of leucine. (C) Box plot and bar chart comparing myotube thickness as measured by microscopy
4 h post the addition of amino acid free media and 2 h post the addition of 2 mM leucine in absolute and relative thickness
respectively. Data are presented as mean +− S.D. (D) Phase contrast images taken 4 h post amino acid free media and
2 h post the addition of 2 mM leucine.
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Optimization of an in vitro bioassay to monitor growth and formation of myotubes in real time
Figure 5 Schematic overview of bioassay
Diagram represents a methodological overview of bioassay, highlighting media changes at critical time points and CI
guidelines in parallel to each stage of growth from day of cell seeding to full myotube differentiation and hypertrophic
analysis on Day 8.
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